Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - MEDICINES CO /DE | y87914exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 22, 2010
The Medicines Company
(Exact Name of Registrant as Specified in Charter)
Delaware | 000-31191 | 04-3324394 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
8 Sylvan Way | ||
Parsippany, New Jersey | 07054 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (973) 290-6000
Not applicable.
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. | Regulation FD Disclosure. |
Beginning on November 22, 2010, senior executives of The Medicines Company (the Company)
delivered a presentation as part of a non-deal roadshow with investors. A copy of the presentation
materials being delivered by the Company are attached to this current report as Exhibit 99.1.
The information furnished pursuant to Item 7.01 of this current report, including Exhibit 99.1,
shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that Section. As such, this information shall not
be incorporated by reference into any of the Companys reports or other filings made with the
Securities and Exchange Commission. The furnishing of the information in this current report is not
intended to, and does not, constitute a determination or admission by the Company that the
information in this current report is material or complete, or that investors should consider this
information before making an investment decision with respect to any security of the Company.
Forward Looking Statements
This current report includes forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. For this purpose, any statements contained herein
regarding the Companys strategy, future operations, prospects, plans and objectives of management,
other than statements of historical facts, are forward-looking statements. The words anticipates,
believes, estimates, expects, intends, may, plans, projects, will, would and
similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. The Company cannot guarantee that it
actually will achieve the results, plans, intentions or expectations expressed or implied in the
Companys forward-looking statements. There are a number of important factors that could cause
actual results, levels of activity, performance or events to differ materially from those expressed
or implied in the forward-looking statements the Company makes. These important factors include the
factors set forth in the Companys Quarterly Report on Form 10-Q filed on November 9, 2010, which
are incorporated herein by reference. The Company specifically disclaims any obligation to update
these forward looking statements
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibit
The following exhibit is furnished as part of this current report on Form 8-K:
(e) Exhibit 99.1 The Medicines Company Non-Deal Roadshow Presentation.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE MEDICINES COMPANY |
||||
Date: November 22, 2010 | By: | /s/ Paul M. Antinori | ||
Name: | Paul M. Antinori | |||
Title: | Senior Vice President and General Counsel | |||
Exhibit Index
Exhibit No. | Description | |||
99.1 | The Medicines Company Non-Deal Roadshow Presentation |